Cyproterone Acetate - Isotope Labelled Standards
References
FAQ's
References
- Rudolf Wiechert, Berlin-Lichterfelde, 6-chloro-1, 2alpha-methylene-delta6-17alpha-hydroxyprogesterone compounds and compositions, US3234093A, Apr 29, 1961, Schering A.-G. (https://www.lens.org/lens/search/patent/list?q=US3234093)
- Cannell, G. R.; Mortimer, R. H.; Thomas, M. J., High-performance liquid chromatographic estimation of cyproterone acetate in human plasma, Journal of Chromatography, Biomedical Applications, Volume: 226, Issue: 2, Pages: 492-7, 1981 DOI: (0.1016/s0378-4347(00)86087-9)
Frequently Asked Questions
2. What are the conditions responsible for the degradation of Cyproterone acetate?
Cyproterone acetate degradation occurs under acidic, alkaline, and peroxide conditions.
3. How do Cyproterone acetate impurities arise in the drug substance?
During drug manufacturing, process-related impurities form in the drug substance due to unreacted raw materials, catalysts, reagents, and solvents.
4. What is the reason for removing Cyproterone acetate impurities from the drug?
Cyproterone acetate impurities need to be removed from the drug so that the drug is safe, stable, and effective for human use.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.